Home › Funds › Anchorage Capital Group, L.L.C. › DNA

Anchorage Capital Group, L.L.C. position in DNA

GINKGO BIOWORKS HOLDINGS INC · Health Care

Anchorage Capital Group, L.L.C. reported holding 1,746,363 shares of DNA (GINKGO BIOWORKS HOLDINGS INC) in its Q2 2026 13F filing — a position valued at US$17.3M, representing 3.84% of its reported portfolio and ranking #3 among its reported holdings. Anchorage Capital Group, L.L.C. has disclosed DNA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.75M sh
Reported value held$17.31M
Portfolio Weight3.84%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Anchorage Capital Group, L.L.C.'s DNA position evolved

Anchorage Capital Group, L.L.C. first disclosed a stake in DNA in Q3 2023 at 69,854,593 shares (US$126.4M). Across 12 filings, Anchorage Capital Group, L.L.C. increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 10 time(s). The most recent filing (Q2 2026) shows 1,746,363 shares valued at US$17.3M. Notable position changes include a 98% trim in Q3 2024 (shares rose 20% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 69.85M $126.44M New
Q4 2023 69.85M $118.05M Hold
Q1 2024 69.85M $81.03M Hold
Q2 2024 69.85M $23.35M Hold
Q3 2024 1.75M $14.23M Reduce
Q4 2024 1.75M $17.15M Hold
Q1 2025 1.75M $9.95M Hold
Q2 2025 1.75M $19.65M Hold
Q3 2025 1.75M $25.46M Hold
Q4 2025 1.75M $14.51M Hold
Q1 2026 1.75M $10.71M Hold
Q2 2026 1.75M $17.31M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DNA and 13F data

DNA (GINKGO BIOWORKS HOLDINGS INC) is a Health Care company. 32 other funds we track also report a position in DNA — the largest reported positions include FORBES J M & CO LLP (US$12.5M), SB INVESTMENT ADVISERS (UK) LTD (US$6.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DNA

All DNA fund holders →

FAQ

How long has Anchorage Capital Group, L.L.C. held DNA?

Anchorage Capital Group, L.L.C. has disclosed DNA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Anchorage Capital Group, L.L.C.'s current position in DNA?

As of Q2 2026, Anchorage Capital Group, L.L.C. holds 1.75M shares of DNA (GINKGO BIOWORKS HOLDINGS INC), valued at $17.31M, representing 3.84% of its reported portfolio and ranking #3.

Has Anchorage Capital Group, L.L.C. been buying or selling DNA?

In the latest 13F filing (Q2 2026), Anchorage Capital Group, L.L.C. held unchanged its position in DNA.

Which other funds hold DNA?

Other major institutional holders of DNA include FORBES J M & CO LLP, SB INVESTMENT ADVISERS (UK) LTD, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.